notch1 d1e11 xp (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
96
Structured Review
Cell Signaling Technology Inc
notch1 d1e11 xp
Notch1 D1e11 Xp, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 615 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/notch1+d1e11+xp/Notch1+XP+Rabbit+mAb/pm41825180-82-58-61
Average 96 stars, based on 615 article reviews
Notch1 D1e11 Xp, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 615 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/notch1+d1e11+xp/Notch1+XP+Rabbit+mAb/pm41825180-82-58-61
Average 96 stars, based on 615 article reviews
notch1 d1e11 xp - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Blocking Assay:Article Title: Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1. Article Snippet: Purpose: To evaluate the efficacy, safety and underlying mechanisms of toripalimab combined with anlotinib as maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) who achieved disease control after first-line platinum-etoposide chemotherapy.. Experimental: Design: A multi-center, single-arm, open-label phase II trial (NCT04363255) enrolled 20 patients with ES-SCLC.. Participants received maintenance therapy with toripalimab (240mgevery3weeks) plus anlotinib (12mgorallyondays1–14ofeach21–daycycle) until disease progression or unacceptable toxicity. Incubation:Article Title: Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1. Article Snippet: Purpose: To evaluate the efficacy, safety and underlying mechanisms of toripalimab combined with anlotinib as maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) who achieved disease control after first-line platinum-etoposide chemotherapy.. Experimental: Design: A multi-center, single-arm, open-label phase II trial (NCT04363255) enrolled 20 patients with ES-SCLC.. Participants received maintenance therapy with toripalimab (240mgevery3weeks) plus anlotinib (12mgorallyondays1–14ofeach21–daycycle) until disease progression or unacceptable toxicity. |